Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial

MT Newswires Live06-10

Nexalin Technology's (NXL) Brazil trial of its Deep Intracranial Frequency Stimulation platform showed a 77.8% response rate for anxiety, along with improvements in depression, insomnia, and overall quality of life, the company said Wednesday.

The eight-week, open-label study conducted at the University of Sao Paulo assessed the company's 15 mA, 77.5 Hz neurostimulation protocol in patients with generalized anxiety disorder and co-occurring insomnia, the company said.

Nexalin said the trial demonstrated rapid and sustained improvements in anxiety and depression, with benefits lasting through an 8-week follow-up period, and no serious adverse events, seizures, or mood-switching events were reported.

The results support the company's planned product launch and commercial expansion in Brazil and further reinforce its non-invasive neurostimulation platform, it added.

Shares of the company were up 1.1% in Wednesday trading.

Price: 0.46, Change: +0.01, Percent Change: +1.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642973421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642973421","market":"hk","top_or_hot":-1,"title":"Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial","media":"MT Newswires Live","content":"<html><body><p> Nexalin Technology's (NXL) Brazil trial of its Deep Intracranial Frequency Stimulation platform showed a 77.8% response rate for anxiety, along with improvements in depression, insomnia, and overall quality of life, the company said Wednesday.</p><p>The eight-week, open-label study conducted at the University of Sao Paulo assessed the company's 15 mA, 77.5 Hz neurostimulation protocol in patients with generalized anxiety disorder and co-occurring insomnia, the company said.</p><p>Nexalin said the trial demonstrated rapid and sustained improvements in anxiety and depression, with benefits lasting through an 8-week follow-up period, and no serious adverse events, seizures, or mood-switching events were reported.</p><p>The results support the company's planned product launch and commercial expansion in Brazil and further reinforce its non-invasive neurostimulation platform, it added.</p><p>Shares of the company were up 1.1% in Wednesday trading.</p><p>Price: 0.46, Change: +0.01, Percent Change: +1.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nexalin Technology's (NXL) Brazil trial of its Deep Intracranial Frequency Stimulation platform showed a 77.8% response rate for anxiety, along with improvements in depression, insomnia, and overall quality of life, the company said Wednesday.</p><p>The eight-week, open-label study conducted at the University of Sao Paulo assessed the company's 15 mA, 77.5 Hz neurostimulation protocol in patients with generalized anxiety disorder and co-occurring insomnia, the company said.</p><p>Nexalin said the trial demonstrated rapid and sustained improvements in anxiety and depression, with benefits lasting through an 8-week follow-up period, and no serious adverse events, seizures, or mood-switching events were reported.</p><p>The results support the company's planned product launch and commercial expansion in Brazil and further reinforce its non-invasive neurostimulation platform, it added.</p><p>Shares of the company were up 1.1% in Wednesday trading.</p><p>Price: 0.46, Change: +0.01, Percent Change: +1.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7016","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642973421","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642973421","pubTimestamp":1781099225,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nexalin Technology's  Brazil trial of its Deep Intracranial Frequency Stimulation platform showed a 77.8% response rate for anxiety, along with improvements in depression, insomnia, and overall quality of life, the company said Wednesday.The eight-week, open-label study conducted at the University of Sao Paulo assessed the company's 15 mA, 77.5 Hz neurostimulation protocol in patients with generalized anxiety disorder and co-occurring insomnia, the company said.Nexalin said the trial demonstrated rapid and sustained improvements in anxiety and depression, with benefits lasting through an 8-week follow-up period, and no serious adverse events, seizures, or mood-switching events were reported.The results support the company's planned product launch and commercial expansion in Brazil and further reinforce its non-invasive neurostimulation platform, it added.Shares of the company were up 1.1% in Wednesday trading.Price: 0.46, Change: +0.01, Percent Change: +1.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7016":"应用软件","NXL.AU":"NUIX LTD","EWZS":"MSCI巴西小盘股ETF-iShares","BK4082":"医疗保健设备","NXL":"Nexalin Technology, Inc."},"translate_title":"Nexalin研究在巴西试验中显示强烈的焦虑和抑郁反应","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NXL.AU":1,"NXL":1,"EWZS":1.5},"content_text":"Nexalin Technology's (NXL) Brazil trial of its Deep Intracranial Frequency Stimulation platform showed a 77.8% response rate for anxiety, along with improvements in depression, insomnia, and overall quality of life, the company said Wednesday.The eight-week, open-label study conducted at the University of Sao Paulo assessed the company's 15 mA, 77.5 Hz neurostimulation protocol in patients with generalized anxiety disorder and co-occurring insomnia, the company said.Nexalin said the trial demonstrated rapid and sustained improvements in anxiety and depression, with benefits lasting through an 8-week follow-up period, and no serious adverse events, seizures, or mood-switching events were reported.The results support the company's planned product launch and commercial expansion in Brazil and further reinforce its non-invasive neurostimulation platform, it added.Shares of the company were up 1.1% in Wednesday trading.Price: 0.46, Change: +0.01, Percent Change: +1.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642973421","isCrawlerRequest":true}